TheraRadar
← Back
Data updated: Jun 28, 2026

ZEALAND PHARMA

Pharma
Metabolic Execution: Good

ZEALAND PHARMA is a pharmaceutical company focused on Metabolic. Key products include ZEGALOGUE.

2021
Since
2
Drugs
-
Trials
0
New Drugs (2yr)

FDA Novel Drug Designations

(2021)
1 Novel
See 1 novel approval →
2021 ZEGALOGUE (DASIGLUCAGON HYDROCHLORIDE)

ZEALAND PHARMA at a Glance

  • Growing R&D activity with 8 trials in last 2 years
  • Fast trial execution (8 months median completion)

ZEALAND PHARMA's Key Drugs

ZEALAND PHARMA's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

ZEALAND PHARMA's Recent FDA Approvals

New NDA/BLA approvals for ZEALAND PHARMA over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

ZEALAND PHARMA's Therapeutic Areas

ZEALAND PHARMA's approved drugs and pipeline span 1 therapeutic area, led by Metabolic. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Metabolic 100%
1 drugs Phase 3: 5 Phase 2: 4 Phase 1: 2

ZEALAND PHARMA's Top Competitors

ZEALAND PHARMA's closest competitors by therapeutic-area and drug-target overlap include Merck, Baxter, and Johnson & Johnson. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Merck big-pharma
Metabolic
Baxter specialty
Metabolic
Johnson & Johnson big-pharma
Metabolic
OTSUKA ICU MEDCL specialty
Metabolic
GSK big-pharma
Metabolic

ZEALAND PHARMA Pipeline Snapshot

ZEALAND PHARMA has 11 active clinical programs from ClinicalTrials.gov — 5 Phase 3, 4 Phase 2 and 2 Phase 1.

5
Phase 3
4
Phase 2
2
Phase 1

Phase 3 Readout Calendar Pro

2 Phase 3 trials with confidence-graded primary completion dates.

Full calendar →
Q3 2028
Glepaglutide 10 mg
Short Bowel Syndrome (SBS)
Estimated · fresh NCT07228403
Q4 2028
Glepaglutide
Short Bowel Syndrome
Estimated · fresh NCT07197944

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Metabolic pipeline focus
  • • 2 Phase 3 readouts tracked
View readout calendar →

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 9/14 completed
  • • Speed: 8 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges